TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06374797
Drug: Auxora
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25 mL/kg (2.0 mg/kg of zegocractin) intravenously (IV) over 4 hours at 0 hours, and then 1.0 mL/kg (1.6 mg/kg of zegocractin) IV over 4 hours at 24, 48, 72 and 96 hours for a total of 5 doses.
Study: NCT06374797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mL/kg IV over 4 hours at 0 hours and then 1.0 mL/kg IV over 4 hours at 24, 48, 72, and 96 hours for a total of 5 doses.
Study: NCT05664217
Drug: NKTR-255 at 1.5 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-255 at 1.5 µg/kg
Study: NCT05664217
Drug: NKTR-255 at 3.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-255 at 3.0 μg/kg
Study: NCT05664217
Drug: NKTR-255 at 3.0/6.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-255 at 3.0/6.0 μg/kg
Study: NCT06274788
Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric patients Pediatric patients with new-onset PNAC~Drug: Omegaven® (fish oil triglycerides) Injectable Emulsion Dose, frequency and duration is a decision of the Investigator
Study: NCT05667623
Drug: 1% OPA-15406 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily administration for 4 weeks/24 weeks.
Study: NCT05718778
Drug: Piamprimab (AK105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piamprilizumab (AK105) combined with radiotherapy for neoadjuvant treatment of soft tissue sarcoma
Study: NCT04947124
Drug: QLS-101ophthalmic solution 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS-101ophthalmic solution 1.0%
Study: NCT04947124
Drug: QLS-101ophthalmic solution 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS-101ophthalmic solution 2.0%
Study: NCT05928585
Drug: HIB210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental monoclonal antibody
Study: NCT05928585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04754152
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable doses of cholinesterase inhibitors were given and the patients were followed up every three months.
Study: NCT01215890
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06692283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablet
Study: NCT06370819
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT05928780
Drug: A1:SG with SHR3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle
Study: NCT05928780
Drug: A2:SG
Normalized name: Amlodipine and Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG 10mg/kg d1, 8
Study: NCT05928780
Drug: B1:SG with SHR1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；
Study: NCT05928780
Drug: C1:SG with SHR3162
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle
Study: NCT05928780
Drug: C2:SG
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SG 10mg/kg d1, 8
Study: NCT05928780
Drug: D1:SG with VEGFRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle
Study: NCT05835310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo via IV infusion
Study: NCT06073093
Drug: SAR441566
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06073093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00277836
Drug: MST-997
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05845736
Drug: Antihypertensive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: number of hypertensive drugs
Study: NCT04242329
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued PD1-inhibitor treatment according to current treatment standards.
Study: NCT06255964
Drug: IAP0971
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
Study: NCT05303909
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of IV gentamicin at a dose of 5 mg/kg infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
Study: NCT05303909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mls of 0.9% normal saline as placebo infused over 30 minutes via a peripheral vein. Followed by administration of YF17D vaccine (stamaril) 0.5mls via subcutaneous injection into the deltoid region of the right or left arm.
Study: NCT05695352
Drug: Meloxicam 15 mg
Normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes
Study: NCT04338126
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: previously described
Study: NCT06068465
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, capsule, once daily by mouth for 6 weeks
Study: NCT04321551
Drug: Testosterone Cyp 200Mg/Ml Inj (in Oil)
Normalized name: TESTOSTERONE CYP 200MG/ML INJ (IN OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1- oxopropoxy)-, (17ß)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.
Study: NCT05599191
Drug: BLU-5937
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of BLU-5937 Tablets
Study: NCT05599191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of matching placebo for BLU-5937 Tablets
Study: NCT06196203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV injection
Study: NCT05203835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match acebilustat by mouth, once a day
Study: NCT06476392
Drug: Melatonin 10 MG
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 Melatonin tablets (each 5 mg) once daily (egual 10 mg/day) in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 5 mg/day.
Study: NCT06476392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets once daily in the evening, 30 min. before going to sleep for 6 weeks. If a participant experiences an adverse event deemed related to the study medication of grade 2 or higher according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 the dose will be reduced to 1 tablet.
Study: NCT04931342
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)
Study: NCT06220773
Drug: BR1019A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 12 weeks.
Study: NCT06220773
Drug: BR1019B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 12 weeks.
Study: NCT06220773
Drug: BR1019C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 12 weeks.
Study: NCT06220773
Drug: BR1019A-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 12 weeks.
Study: NCT06220773
Drug: BR1019B-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 12 weeks.
Study: NCT06220773
Drug: BR1019C-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 12 weeks.
Study: NCT05836805
Drug: [14C]XZP-3621
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extemporaneously compounded oral suspension solution of \[14C\]XZP-3621 (400 mg/200 µCi)
Study: NCT05525013
Drug: Simvastatin Powder
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin gel placed as an intracanal medication
Study: NCT05525013
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide intracanal medication
Study: NCT05216653
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2，po，bid，d1-14
Study: NCT05240898
Drug: RO7623066
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally in capsule
Study: NCT06075264
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical placebo ointment
Study: NCT05762211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT05836584
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05836584
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05836584
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002064
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04846036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of matching placebo twice daily
Study: NCT05411809
Drug: drug adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.
Study: NCT02987257
Drug: Harmonized supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harmonized supportive care with and etanercept placebo days 1 and 4
Study: NCT02701023
Drug: MitoGel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
Study: NCT06227910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib matched placebo capsules.
Study: NCT05010668
Drug: cryoablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoablation treatment starts at day 0.
Study: NCT05295732
Drug: TMB-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TMB-001 0.05% QD/BID
Study: NCT05295732
Drug: Matching Vehicle
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Vehicle
Study: NCT05665881
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vasopressor
Study: NCT05206773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT05184452
Drug: PGDM1400LS (20mg/kg, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg to be administered via IV infusion
Study: NCT05184452
Drug: PGDM1400LS (40mg/kg, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg to be administered via IV infusion
Study: NCT05184452
Drug: PGDM1400LS (1.4g, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4gram to be administered via IV infusion
Study: NCT05184452
Drug: PGDM1400LS (1.4g, SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4gram to be administered via SC infusion
Study: NCT05184452
Drug: VRC07-523LS (20mg/kg, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS 20mg/kg administered via IV infusion
Study: NCT05184452
Drug: VRC07-523LS (20mg/kg, SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS 20mg/kg administered via SC infusion
Study: NCT05184452
Drug: VRC07-523LS (1.4g, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS 1.4g administered via IV infusion
Study: NCT05184452
Drug: VRC07-523LS (1.4g, SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS 1.4g administered via SC infusion
Study: NCT05184452
Drug: VRC07-523LS (40mg/kg, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC07-523LS 40mg/kg administered via IV infusion
Study: NCT05184452
Drug: PGT121.414.LS (20mg/kg, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 20mg/kg administered via IV infusion
Study: NCT05184452
Drug: PGT121.414.LS (1.4g, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 1.4g administered via IV infusion
Study: NCT05184452
Drug: PGT121.414.LS (40mg/kg, IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGT121.414.LS 40mg/kg administered via IV infusion
Study: NCT04275531
Drug: Anesthesia Agent
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: various anesthetic agents used in both general and regional anesthesia
Study: NCT05247255
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL block with saline
Study: NCT05453500
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05453500
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06505148
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered alternatively with other drug
Study: NCT06505148
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered alternatively with other drug
Study: NCT05285085
Drug: Statin
Normalized name: Statin
DrugBank: Apstatin (DB04092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin use
Study: NCT06451861
Drug: Anthracyclines or anthraquinones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction Therapy
Study: NCT04782661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered orally.
Study: NCT05166109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Vamorolone 4.0% wt/wt oral suspension will be administered for the duration of the study.
Study: NCT05262179
Drug: CTO0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop/ once or three times a day/ for 17 days divided into stage2
Study: NCT06439602
Drug: AR882 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Capsule
Study: NCT06439602
Drug: AR882 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Capsule
Study: NCT06439602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Solid Oral Capsule Placebo
Study: NCT06287073
Drug: JARDIANCE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: JARDIANCE®
Study: NCT05766670
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intramedullary calcium sulfate antibiotic depot will be mixed sterilely to include at minimum 20cc calcium sulfate powder mixed with 1g of vancomycin powder and 1.2g of tobramycin powder per 10cc of calcium sulfate.
Study: NCT05177094
Drug: LY3526318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05177094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00608816
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
Study: NCT00608816
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
Study: NCT06244992
Drug: PTT-936
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).
Study: NCT06244992
Drug: Combination of PTT-936 and anti-PD-1/L1 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
Study: NCT06263959
Drug: Placebo to match GST-HG131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GST-HG131 will be administered.
Study: NCT05768932
Drug: BAL0891
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)
Study: NCT05981040
Drug: ZYIL1 capsules 25 mg and 50 mg Placebo
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYIL1 capsules 25 mg for oral administration + matching placebo of 50 mg ZYIL1 capsule
Study: NCT05981040
Drug: ZYIL1 capsules 50 mg and 25 mg Placebo
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYIL1 capsules 50 mg for oral administration + matching placebo of 25 mg ZYIL1 capsule
Study: NCT05223582
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients would get medical castration.
Study: NCT05981040
Drug: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYIL1 capsules 25 mg for oral administration + ZYIL1 capsules 50 mg for oral administration
Study: NCT05981040
Drug: Matching placebo 25 mg and Matching placebo 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of 25 mg ZYIL1 capsule + Matching placebo of 50 mg ZYIL1 capsule
Study: NCT04862234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
Study: NCT05757102
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI will be administered.
Study: NCT06292013
Drug: Lepodisiran Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06292013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05100095
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy to the primary tumor and/or lymph nodes
Study: NCT04455841
Drug: INCB000928
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB000928 will be administered at protocol defined dose.
Study: NCT05104463
Drug: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
Study: NCT04570956
Drug: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day
Study: NCT04570956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill or placebo gel
Study: NCT03822793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.
Study: NCT03822793
Drug: Group 4: perfusion of 3000 mg Exacyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.
Study: NCT06178055
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
Study: NCT05316922
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
Study: NCT06312345
Drug: Drug: ciprofol injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
Study: NCT05498675
Drug: ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no treatment allocation. Patients administered angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists (ACEI/ARB) by prescription that have started before inclusion of the patient enrolled into the study and defined as ACEI/ARB group.~Including:~benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan.
Study: NCT05834777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride will be administered as the same rate as icatibant
Study: NCT05526196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried flower cigarette with both placebo tobacco and cannabis
Study: NCT05716763
Drug: Tramadol Hydrochloride 100 MG/ML Oral Solution (Contramal(r))
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg (20 drops) single dose